Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process: 2016-2024

Historic Work In Process for Heron Therapeutics (HRTX) over the last 9 years, with Dec 2024 value amounting to $27.2 million.

  • Heron Therapeutics' Work In Process rose 43.54% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 43.54%. This contributed to the annual value of $27.2 million for FY2024, which is 86.87% up from last year.
  • Per Heron Therapeutics' latest filing, its Work In Process stood at $27.2 million for FY2024, which was up 86.87% from $14.6 million recorded in FY2023.
  • Heron Therapeutics' Work In Process' 5-year high stood at $27.2 million during FY2024, with a 5-year trough of $6.8 million in FY2020.
  • For the 3-year period, Heron Therapeutics' Work In Process averaged around $20.8 million, with its median value being $20.7 million (2022).
  • Per our database at Business Quant, Heron Therapeutics' Work In Process slumped by 45.53% in 2020 and then soared by 205.75% in 2021.
  • Heron Therapeutics' Work In Process (Yearly) stood at $6.8 million in 2020, then soared by 205.75% to $20.9 million in 2021, then declined by 1.01% to $20.7 million in 2022, then fell by 29.79% to $14.6 million in 2023, then surged by 86.87% to $27.2 million in 2024.